Breaking Finance News

Immune Design (NASDAQ:IMDZ) target price raised to $20.00, reported today by RBC Capital

Yesterday Immune Design (NASDAQ:IMDZ) traded -4.30% lower at $9.30. The company’s 50-day moving average is $9.76 and its 200-day moving average is $7.87. The last stock close price is up 13.06% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 127,340 shares of the stock were exchanged, down from an average trading volume of 194,689

Immune Design (NASDAQ:IMDZ) had its target price raised to $20.00 by RBC Capital in a report released 9/15/2017. The new target price indicates a possible upside of 1.15% based on the company's last stock close price.

See Chart Below

Immune Design (NASDAQ:IMDZ)

Immune Design has a 52 week low of $4.50 and a 52 week high of $13.05 The company’s market cap is currently $0.

About Immune Design (NASDAQ:IMDZ)

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is engaged in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials. CMB305 is targeting the NY-ESO-1 tumor antigen, in which a priming agent called LV305 from its ZVex platform is dosed sequentially with an agent from its GLAAS platform. G100 leverages the range of endogenous antigens found in the tumor microenvironment, including neoantigens.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.